QGEN or EXAS: Which Is the Better Value Stock Right Now?

Core Insights - Investors in the Medical - Biomedical and Genetics sector should consider Qiagen (QGEN) and Exact Sciences (EXAS) for potential value opportunities [1] Valuation Metrics - Both QGEN and EXAS currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions and improving earnings outlooks [3] - QGEN has a forward P/E ratio of 20.46, significantly lower than EXAS's forward P/E of 345.69, suggesting QGEN may be undervalued [5] - The PEG ratio for QGEN is 2.44, while EXAS has a much higher PEG ratio of 11.81, indicating QGEN's expected earnings growth is more favorable [5] - QGEN's P/B ratio is 3.13 compared to EXAS's P/B of 4.35, further supporting QGEN as the more attractive value option [6] - Based on various valuation metrics, QGEN holds a Value grade of B, while EXAS has a Value grade of C, reinforcing QGEN's position as the superior value stock [6]